


## cangrelor tetrasodium

### Chemical Properties

CAS No. :	163706-36-3
Formula:	C17H21Cl2F3N5Na4O12P3S2
Molecular Weight:	864.29
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



### Biological Description

Description	Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects.
Targets(IC50)	GPCR,P2Y Receptor
In vitro	cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.Cangrelor is also a well-known anti-platelet agent. cangrelor (10 mg/kg) not only significantly decreased BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreased the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice. In addition, cangrelor decreased the number of CD40 and MPO double positive neutrophils and the expression level of CD40 in BLM-treated mouse lungs[1].

### Solubility Information

Solubility	H2O: 80 mg/mL (92.56 mM),Sonication is recommended. DMSO: 12.56 mg/mL (14.53 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.16 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.157 mL	5.7851 mL	11.5702 mL
5 mM	0.2314 mL	1.157 mL	2.314 mL
10 mM	0.1157 mL	0.5785 mL	1.157 mL
50 mM	0.0231 mL	0.1157 mL	0.2314 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Tianwei Zhan, Taofeng Wei. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. *Mol Immunol.* 2020 Apr;120:83-92.

K. Bekő, B. Koványi, F. Göloncsér, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain[J]. *Journal of Thrombosis and Haemostasis*, 2017.

Bhattad VB, et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. *Ann Transl Med.* 2019;7(17):408.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481